Comparative Pharmacology
Head-to-head clinical analysis: LUMENHANCE versus OPTIMARK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMENHANCE versus OPTIMARK.
LUMENHANCE vs OPTIMARK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
Gadolinium-based MRI contrast agent that increases signal intensity by shortening T1 relaxation time in tissues where it accumulates.
1 mg intravenously once daily
0.1 mmol/kg (0.2 mL/kg) intravenously as a single bolus injection; not to exceed 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. In patients with severely impaired renal function (GFR <30 mL/min), half-life is significantly prolonged (up to 20 hours).
LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes.
Primarily renal excretion (glomerular filtration). >95% of the administered dose is eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent